|
|
|
|
|
Cardene: profile and news
Assemblyman backing prescription for safety Mar 4, 2006 PDL BioPharma Announces Fourth Quarter and Full Year 2005 ... Feb 27, 2006 PDL BioPharma Announces Fourth Quarter and Full Year 2005 ... Feb 27, 2006 PDL's Potent Pick-Me-Up Feb 27, 2006 PDL BioPharma Set For Years Of Growth Feb 24, 2006 Protein Design Labs Becomes PDL BioPharma Jan 9, 2006 Caldwell: An update on Veterans' benefits Dec 7, 2005 Police Blotter: Posted 12/06 Dec 6, 2005 Obama against review of stress disorder cases Oct 2, 2005 PDL Announces Strong Second Quarter 2005 Financial Results Aug 4, 2005 Packers pass on defense, grab Brett Favre's heir apparent Apr 23, 2005 College: Texas A&M Apr 23, 2005 Biotech's Momentum Stalls Apr 1, 2005 Protein Design Labs Completes Acquisition of ESP Pharma and ... Mar 24, 2005 Protein Design Labs Announces Above Consensus Full-Year and Fourth ... Mar 14, 2005 Other information Indication Used for the management of patients with chronic stable angina Pharmacology Nicardipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nicardipine is similar to other peripheral vasodilators. Nicardipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. Mechanism Of Action By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. Drug Category Antiarrhythmic Agents; Vasodilator Agents; Antihypertensive Agents; Dihydropyridines; ATC:C08CA04 Brand Names/Synonyms Cardene; Cardene Sr; Nicardipine; Nicardipine Hcl; Nicardipino [Inn-Spanish]; Nicardipinum [Inn-Latin]; YC-93 Dosage Forms CAPSULE Absorption While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state. Interactions -->Interactions for Nicardipine: Beta-Blockers In controlled clinical studies, adrenergic beta-receptor blockers have been frequently administered concomitantly with nicardipine HCl. The combination is well tolerated. Cimetidine Cimetidine increases nicardipine HCl plasma levels. Patients receiving the two drugs concomitantly should be carefully monitored. Digoxin Some calcium blockers may increase the concentration of digitalis preparations in the blood. Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated. Maalox®* Coadministration of Maalox TC had no effect on nicardipine HCl absorption. Fentanyl Anesthesia Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta-blocker and a calcium channel blocker. Even though such interactions were not seen during clinical studies with nicardipine HCl, an increased volume of circulating fluids might be required if such an interaction were to occur. Cyclosporine Concomitant administration of nicardipine and cyclosporine levels. Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine. When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered. Chemical IUPAC Name methyl2-(benzyl-methyl-amino)ethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical Formula C26H29N3O6 Half Life 8.6 hours Drug Type Approved Drug # Accession No APRD00088 CAS Registry Number 55985-32-5 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |